Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340883 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 1 study, sponsored by Chinook Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03340883 is a Phase 1 study that was terminated before completion, run by Chinook Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT03340883, a Phase 1 study, was terminated before completion, sponsored by Chinook Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
Interventions
- BIOLOGICAL BION-1301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03340883
The ClinicalTrials.gov registry entry for NCT03340883 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chinook Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BION-1301 is the first listed.
NCT03340883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03340883 about?
NCT03340883 is a clinical study titled "Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)". This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
What is the current status of trial NCT03340883?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-11-15. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03340883?
The interventions under investigation include: BION-1301 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03340883?
This trial is sponsored by Chinook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.